Want to see GDRX full AI Analyst Report?
GDRX Stock Chart & Stats
$3.65
$0.09(3.04%)
At close: 4:00 PM EDT
$3.65
$0.09(3.04%)
Day’s Range― - ―
52-Week Range$1.77 - $5.81
Previous CloseN/A
Volume1.06M
Average Volume (3M)1.65M
Market Cap
$1.18B
Enterprise Value$1.25K
Total Cash (Recent Filing)$296.11M
Total Debt (Recent Filing)$538.95M
Price to Earnings (P/E)65.6
Beta1.04
Next Earnings
Nov 10, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding107,181,200
10 Day Avg. Volume1,823,597
30 Day Avg. Volume1,649,048
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)1.21
P/FCF Ratio5.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.21Price Target Upside15.37% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)0.3
Revenue Forecast (FY)$799.78M
Bulls Say, Bears Say
Bulls Say
Strong And Improving Cash GenerationSustained positive operating and free cash flow provides funding for product investment, supports financial resilience, and indicates stronger cash conversion than the company’s thin reported profitability alone would suggest.
Rapid Pharma Direct Growth And Raised GuidancePharma Direct is becoming a substantial growth engine and may offset weaker prescription transactions. Its scale, rapid expansion, and contribution to raised guidance improve the likelihood of a more durable growth profile.
Subscription Growth And Platform DiversificationGrowing subscriptions can provide recurring, higher-lifetime-value revenue and deepen user engagement. Companion and Employer Direct also broaden GoodRx beyond transaction fees, supporting a more diversified business model.
Bears Say
Sharp Revenue Decline And Thin ProfitabilityThe steep top-line contraction shows that the business transition has not yet produced consistent aggregate growth. Thin profitability leaves less buffer to absorb execution challenges or investment needs.
Declining Users And Moderating Prescription TransactionsA shrinking active-user base and moderating legacy transactions could weaken network scale and near-term monetization. New subscription adoption must offset this erosion for the platform to sustain durable growth.
Limited KPI Visibility And Margin UncertaintyReduced disclosure makes it harder to assess retention and underlying prescription activity during the business-model shift. Higher subscription servicing costs and absent gross-margin guidance add uncertainty to margin durability.
GoodRx Holdings News
GDRX FAQ
What was GoodRx Holdings’s price range in the past 12 months?
GoodRx Holdings lowest stock price was $1.77 and its highest was $5.81 in the past 12 months.
What is GoodRx Holdings’s market cap?
GoodRx Holdings’s market cap is $1.18B.
When is GoodRx Holdings’s upcoming earnings report date?
GoodRx Holdings’s upcoming earnings report date is Nov 10, 2026 which is in 68 days.
How were GoodRx Holdings’s earnings last quarter?
GoodRx Holdings released its earnings results on Aug 05, 2026. The company reported $0.08 earnings per share for the quarter.
Is GoodRx Holdings overvalued?
According to Wall Street analysts GoodRx Holdings’s price is currently Undervalued.
Does GoodRx Holdings pay dividends?
GoodRx Holdings does not currently pay dividends.
What is GoodRx Holdings’s EPS estimate?
GoodRx Holdings’s EPS estimate is 0.08.
How many shares outstanding does GoodRx Holdings have?
GoodRx Holdings has 107,181,200 shares outstanding.
What happened to GoodRx Holdings’s price movement after its last earnings report?
GoodRx Holdings reported an EPS of $0.08 in its last earnings report. Following the earnings report the stock price went up 13.761%.
Which hedge fund is a major shareholder of GoodRx Holdings?
Currently, no hedge funds are holding shares in GDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GoodRx Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.21 (15.37% Upside)
$4.21 (15.37% Upside)
Blogger Sentiment
Neutral
GDRX Sentiment 67%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 611.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GoodRx Holdings
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.
GDRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong execution and visible, high-growth revenue engines (Pharma Direct and subscriptions) with meaningful beats and raised full-year guidance. These positives were tempered by declines in monthly active consumers, moderation of traditional prescription transaction revenue and limited disclosure of prescription-level KPIs during a strategic transition. Management framed the shifts as intentional investments in more durable, higher-LTV revenue streams and signaled confidence in sustained growth, while acknowledging some short-term metric and disclosure trade-offs.View all GDRX earnings summariesGDRX Revenue Breakdown
73.41% Prescription transactions
12.58% Subscription
11.34% Pharma manufacturer solutions
2.67% Other
GDRX Stock 12 Month Forecast
Average Price Target
$4.21
▲(15.37% Upside)
Technical Analysis
Ownership Overview
12.75% Insiders
9.86% Mutual Funds
9.08% Other Institutional Investors
59.74% Public Companies and
Individual Investors